01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Tiziana Life Sciences #TILS – Result of GM May 6, 2020 – Posted in: Tiziana Life Sciences (TILS)

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION At the General Meeting of the Company held at 11.00 a.m. on 6 May 2020, the resolutions to seek additional authorities to issue…

Continue reading

Tiziana Life Sciences (Nasdaq: TSLA / AIM: TILS) Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 million March 12, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, March 12, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announced   the pricing of its underwritten follow-on public offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. Tiziana will issue 3,333,333 ADSs (representing 16,666,665 new ordinary shares…

Continue reading

Tiziana Life Sciences #TILS – Result of GM, Resolutions Duly Passed February 20, 2020 – Posted in: Tiziana Life Sciences (TILS)

At the General Meeting of the Company held at 10.00 a.m. on 20 February 2020 at the offices of Orrick, Herrington & Sutcliffe (UK) LLP, 107 Cheapside, London, EC2V 6DN, the resolutions to seek additional authorities to issue shares and to disapply pre-emption rights were duly passed. The results of the proxy voting will be available shortly on the Company’s website, www.tizianalifesciences.com. The person who arranged for the release of this announcement was Tiziano Lazaretti,…

Continue reading

Tiziana Life Sciences #TILS Announces Proposed U.S. Public Offering of ADSs February 17, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, February 17, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the commencement of an underwritten public offering in the United States of  American Depositary Shares (“ADSs”), representing ordinary shares of nominal value £0.03 each in the capital of the…

Continue reading